Related Experiment Video
Updated: May 28, 2025
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Safety reporting in neonatal clinical trials: reflections towards optimal, globally relevant approaches
Louise F Hill1, Christina W Obiero2, Adrie Bekker3
1Centre for Neonatal and Paediatric Infection, University of London, City St George's, London, UK.
Insights
Collecting adverse event (AE) data in neonatal clinical trials is crucial but challenging. Improving AE reporting methods ensures essential safety data for drug development in this vulnerable population.
Area of Science:
- Neonatal research
- Clinical trials
- Pharmacovigilance
Background:
- Adverse event (AE) collection is vital for clinical trial evidence generation and safety reporting.
- AE assessment in neonates presents unique challenges due to population heterogeneity and comorbidities.
- Regulatory focus on neonatal drug development highlights the need for specific dosing and safety data.
Purpose of the Study:
- To discuss challenges in AE collection and reporting in neonatal trials.
- To identify areas for improvement in safety reporting methodologies.
- To emphasize the need for pragmatic approaches, especially in resource-constrained settings.
Main Methods:
- This commentary reflects on existing challenges in AE reporting.
- It discusses the importance of aligning safety reporting methodology with trial outcomes.
- It considers the specific needs of resource-limited settings for pharmacovigilance.
Main Results:
- Current AE collection methods in neonatal trials face significant challenges.
- There is a need for optimized and pragmatic safety reporting strategies.
- Improved AE data collection is essential for generating reliable safety profiles.
Conclusions:
- Enhanced AE data collection is critical for neonatal drug development.
- Methodological improvements can reduce the burden on trial sites.
- Pragmatic safety reporting is essential for public health, particularly in resource-limited environments.
Abstract:
Adverse event (AE) collection is a key part of evidence generation in clinical trials and an integral element of safety reporting. AE assessment and documentation is particularly challenging in neonates who are a heterogeneous population with high rates of co-morbidities. Neonatal research is finally gaining the attention of regulators regarding drug development and the need for optimal dosing specific to this population. However, further efforts are necessary to ensure that adverse events (AEs) are adequately collected, allowing for the generation of essential safety data. It is also crucial that the methodology used aligns with the intended trial outcomes to minimise the burden on trial sites. In resource-constrained settings, where pharmacovigilance implementation can be particularly challenging, a pragmatic approach to safety reporting is even more important given the significant public health need for effective drugs. This commentary reflects on some of the challenges and potential areas of improvement in safety reporting that could be addressed in future neonatal-focused trials.
More Related Videos
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:21Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:26Types of Reports III: Telephone and Verbal Reports
Here's an overview of each type:
Telephone Orders